Search

Displaying results 6061 - 6070 of 7017 in total
  1. Drug

    Ofirnoflast

    go.drugbank.com/drugs/DB21679
    Investigational

    Ofirnoflast is a small molecule drug. The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor. … Ofirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da.

  2. Drug

    UK-432097

    go.drugbank.com/drugs/DB12691
    Investigational

    UK-432,097 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.

    Categories: Adenosine A receptor agonists, Adenosine A2 Receptor Agonists
  3. Drug

    Prinomastat

    go.drugbank.com/drugs/DB05100
    Investigational

    As a lipophilic agent, prinomastat crosses the blood-brain barrier. … Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity.

  4. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  5. Drug

    Carbomycin

    go.drugbank.com/drugs/DB11383
    ExperimentalVet approved

    This antibacterial is obtained from _Streptomyces halstedii_ and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains.

    Synonyms: Carbomycin A, Magnamycin A
  6. Drug

    Risvutatug rezetecan

    go.drugbank.com/drugs/DB23560
    Investigational

    Risvutatug rezetecan (GSK5764227) is a novel investigational B7-H3-targeted antibody-drug conjugate. … It is under investigation in clinical trial NCT06885034 (A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers

  7. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis. … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  8. Drug

    Thienylfentanyl

    go.drugbank.com/drugs/DB09180
    ExperimentalIllicit

    Thienylfentanyl is a fentanyl analog analgesic that was sold on the black market in the 1980s until the Federal Analog Act scheduled drugs based on structural similarity rather than scheduling drugs individually … Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted for phenethyl bromide.

  9. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    Androstenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. … Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a

  10. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    A rare genetic disorder, hyper-beta-alaninemia, has been reported. … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].